Biosimilars
Page 2 • 8 itemsTrack global biosimilar approvals, market entry strategies, and regulatory pathways. Gain critical intelligence for your pharmaceutical BD and investment decisions.
Biosimilar Landscape in Japan: Impact of PMDA Updates & SAKIGAKE 2024
This article delves into the impact of recent PMDA updates and the SAKIGAKE initiative on the biosimilar market in Japan, highlighting implications for drugs like adalimumab.
Biosimilar Market Growth Japan: Impact of PMDA's 2024 Interchangeability Guidelines
This article examines how the PMDA's 2024 interchangeability guidelines will influence the growth of the biosimilar market in Japan, focusing on drugs like Adalimumab.
ICH Guidelines Biosimilar Development: Impact on APAC Approval Timelines
This article delves into ICH guidelines for biosimilar development, highlighting their influence on approval timelines in the APAC region for critical therapies.
Biosimilar Market Growth India: Key Drivers, Challenges & Opportunities
The biosimilar market in India is poised for significant growth, driven by increasing demand for affordable biologics like Trastuzumab, alongside various challenges and opportunities.
Adalimumab Biosimilars Uptake: Australia vs Japan Market Analysis
This article analyzes the market dynamics of Adalimumab biosimilars in Australia and Japan, highlighting differences in uptake and patient access for rheumatoid arthritis.
PMDA Biosimilar Framework: Impact on Trastuzumab Biosimilars in Japan
This article delves into the PMDA biosimilar framework and its significant influence on the development and approval of trastuzumab biosimilars in Japan.
NMPA Biosimilar Approval Pathway: What You Need to Know
Explore the NMPA biosimilar approval pathway for adalimumab, focusing on essential steps and requirements for gaining market access in China.
Bevacizumab Biosimilar Approval China: NMPA Greenlights First Biosimilar
The NMPA has approved the first biosimilar of Bevacizumab, a groundbreaking step for cancer treatment accessibility in China.